Leap therapeutics provides update on beigene option agreement for dkn-01

Distinguish trial of dkn-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration cambridge, mass. , march 16, 2023 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that beigene's option under the exclusive option and license agreement between leap and beigene granting rights in certain asian territories to dkn-01, leap's anti-dkk1 monoclonal antibody, has expired in accordance with the terms of the agreement.
LPTX Ratings Summary
LPTX Quant Ranking